Windlas Biotech [WINDLAS] vs Sun Pharma Advanced [SPARC] Detailed Stock Comparison

Windlas Biotech
NSE
Loading...

Sun Pharma Advanced
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Windlas Biotech wins in 11 metrics, Sun Pharma Advanced wins in 7 metrics, with 0 ties. Windlas Biotech appears stronger overall.
View Metrics Details
Vital Metrics Comparison
Metric | Windlas Biotech | Sun Pharma Advanced | Better |
---|---|---|---|
P/E Ratio (TTM) | 34.01 | -13.34 | Sun Pharma Advanced |
Price-to-Book Ratio | 4.34 | -21.04 | Sun Pharma Advanced |
Debt-to-Equity Ratio | 6.45 | -1.24 | Sun Pharma Advanced |
PEG Ratio | 1.12 | 0.29 | Sun Pharma Advanced |
EV/EBITDA | 19.37 | -16.99 | Sun Pharma Advanced |
Profit Margin (TTM) | 8.20% | -53.22% | Windlas Biotech |
Operating Margin (TTM) | 9.08% | -568.05% | Windlas Biotech |
EBITDA Margin (TTM) | 9.08% | N/A | N/A |
Return on Equity | 12.06% | 157.88% | Sun Pharma Advanced |
Return on Assets (TTM) | 8.02% | -102.08% | Windlas Biotech |
Free Cash Flow (TTM) | $159.93M | $-3.71B | Windlas Biotech |
Dividend Yield | 1.23% | N/A | N/A |
1-Year Return | 24.64% | -34.25% | Windlas Biotech |
Price-to-Sales Ratio (TTM) | 2.76 | 70.46 | Windlas Biotech |
Enterprise Value | $19.88B | $48.18B | Sun Pharma Advanced |
EV/Revenue Ratio | 2.50 | 74.59 | Windlas Biotech |
Gross Profit Margin (TTM) | 38.25% | -10.68% | Windlas Biotech |
Revenue per Share (TTM) | $380 | $2 | Windlas Biotech |
Earnings per Share (Diluted) | $30.80 | $-9.19 | Windlas Biotech |
Beta (Stock Volatility) | 0.28 | 0.31 | Windlas Biotech |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Windlas Biotech vs Sun Pharma Advanced Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
Stock | 1D | 1W | 1M | 3M | 6M | YTD |
---|---|---|---|---|---|---|
Windlas Biotech | 2.22% | 13.63% | 14.98% | 4.29% | 36.23% | 0.34% |
Sun Pharma Advanced | 2.40% | -3.92% | -13.01% | -6.93% | -0.76% | -30.12% |
Long-term Returns
Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
---|---|---|---|---|---|---|
Windlas Biotech | 24.64% | 389.60% | 185.66% | 185.66% | 185.66% | 185.66% |
Sun Pharma Advanced | -34.25% | -41.92% | -22.97% | -66.04% | 46.46% | -51.75% |
Performance & Financial Health Analysis: Windlas Biotech vs Sun Pharma Advanced
Metric | WINDLAS | SPARC |
---|---|---|
Market Information | ||
Market Cap | ₹21.95B | ₹45.51B |
Market Cap Category | Small cap | Small cap |
10 Day Avg. Volume | 153,326 | 286,063 |
90 Day Avg. Volume | 90,007 | 352,245 |
Last Close | ₹1,070.80 | ₹143.61 |
52 Week Range | ₹665.10 - ₹1,198.25 | ₹109.30 - ₹241.00 |
% from 52W High | -10.64% | -40.41% |
All-Time High | ₹1,198.25 (Nov 04, 2024) | ₹875.00 (Apr 24, 2006) |
% from All-Time High | -10.64% | -83.59% |
Growth Metrics | ||
Quarterly Revenue Growth | 0.20% | -0.43% |
Quarterly Earnings Growth | 0.31% | -0.43% |
Financial Health | ||
Profit Margin (TTM) | 0.08% | -0.53% |
Operating Margin (TTM) | 0.09% | -5.68% |
Return on Equity (TTM) | 0.12% | 1.58% |
Debt to Equity (MRQ) | 6.45 | -1.24 |
Cash & Liquidity | ||
Book Value per Share (MRQ) | ₹241.38 | ₹-6.69 |
Cash per Share (MRQ) | ₹114.20 | ₹0.06 |
Operating Cash Flow (TTM) | ₹396.84M | ₹-3,484,287,000 |
Levered Free Cash Flow (TTM) | ₹609.94M | ₹-3,425,094,000 |
Dividends | ||
Last 12-Month Dividend Yield | 1.23% | N/A |
Last 12-Month Dividend | ₹11.30 | N/A |
Valuation & Enterprise Metrics Analysis: Windlas Biotech vs Sun Pharma Advanced
Metric | WINDLAS | SPARC |
---|---|---|
Price Ratios | ||
P/E Ratio (TTM) | 34.01 | -13.34 |
Forward P/E | N/A | 2.53 |
PEG Ratio | 1.12 | 0.29 |
Price to Sales (TTM) | 2.76 | 70.46 |
Price to Book (MRQ) | 4.34 | -21.04 |
Market Capitalization | ||
Market Capitalization | ₹21.95B | ₹45.51B |
Enterprise Value | ₹19.88B | ₹48.18B |
Enterprise Value Metrics | ||
Enterprise to Revenue | 2.50 | 74.59 |
Enterprise to EBITDA | 19.37 | -16.99 |
Risk & Other Metrics | ||
Beta | 0.28 | 0.31 |
Book Value per Share (MRQ) | ₹241.38 | ₹-6.69 |
Financial Statements Comparison: Windlas Biotech vs Sun Pharma Advanced
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
Metric (MRQ) | WINDLAS | SPARC |
---|---|---|
Revenue/Sales | ₹2.03B | ₹96.40M |
Cost of Goods Sold | ₹1.25B | ₹106.70M |
Gross Profit | ₹775.14M | ₹-10.30M |
Research & Development | N/A | N/A |
Operating Income (EBIT) | ₹172.13M | ₹-547.60M |
EBITDA | ₹304.85M | ₹-429.40M |
Pre-Tax Income | ₹208.23M | ₹-518.10M |
Income Tax | ₹45.42M | ₹600,000 |
Net Income (Profit) | ₹162.81M | ₹-518.70M |
Balance Sheet & Liquidity Metrics (MRQ)
Metric (MRQ) | WINDLAS | SPARC |
---|---|---|
Cash & Equivalents | ₹4.24M | ₹19.64M |
Total Current Assets | ₹5.25B | ₹261.97M |
Total Current Liabilities | ₹2.49B | ₹3.74B |
Long-Term Debt | ₹22.51M | ₹1.07B |
Total Shareholders Equity | ₹5.06B | ₹-2.17B |
Retained Earnings | N/A | ₹-23.22B |
Property, Plant & Equipment | ₹2.19B | ₹178.02M |
Cash Flow Statement Comparison (MRQ)
Metric (MRQ) | WINDLAS | SPARC |
---|---|---|
Operating Cash Flow | N/A | N/A |
Capital Expenditures | N/A | N/A |
Free Cash Flow | N/A | N/A |
Debt Repayment | N/A | N/A |
Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
Metric | WINDLAS | SPARC |
---|---|---|
Shares Short | N/A | N/A |
Short Ratio | N/A | N/A |
Short % of Float | N/A | N/A |
Average Daily Volume (10 Day) | 153,326 | 286,063 |
Average Daily Volume (90 Day) | 90,007 | 352,245 |
Shares Outstanding | 20.96M | 324.52M |
Float Shares | 7.85M | 91.74M |
% Held by Insiders | 0.64% | 0.73% |
% Held by Institutions | 0.10% | 0.02% |
Dividend Analysis & Yield Comparison: Windlas Biotech vs Sun Pharma Advanced
Metric | WINDLAS | SPARC |
---|---|---|
Last 12-Month Dividend | ₹11.30 | N/A |
Last 12-Month Dividend Yield | 1.23% | N/A |
3-Year Avg Annual Dividend | ₹6.27 | N/A |
3-Year Avg Dividend Yield | 0.96% | N/A |
3-Year Total Dividends | ₹18.80 | N/A |
Ex-Dividend Date | Jul 21, 2025 | N/A |